Compare SAIC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIC | ELVN |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.2B |
| IPO Year | 2013 | 2020 |
| Metric | SAIC | ELVN |
|---|---|---|
| Price | $125.82 | $57.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $110.50 | $43.40 |
| AVG Volume (30 Days) | 374.5K | ★ 986.1K |
| Earning Date | 06-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 7.39 | 3.17 |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $7,262,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.65 | N/A |
| P/E Ratio | $49.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $81.08 | $14.79 |
| 52 Week High | $129.70 | $62.32 |
| Indicator | SAIC | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 68.33 | 59.86 |
| Support Level | $90.75 | $25.63 |
| Resistance Level | N/A | $62.32 |
| Average True Range (ATR) | 3.29 | 2.69 |
| MACD | 0.19 | -0.29 |
| Stochastic Oscillator | 94.08 | 63.03 |
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management, operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments, which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.